Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
Novavaxto deliver 350 million doses beginning Q3 2021
- 1.1 billion doses of
Novavaxvaccine to be available to countries participating in COVAX Serum Institute of Indiato provide balance of doses for LMICs
- Underscores commitment to global equitable access to
"This is a tremendous opportunity to partner with global organizations focused on accelerating equitable access to safe and effective COVID-19 vaccines, particularly in countries where vaccination rates are currently low," said
Under the APA,
"CEPI's investments to accelerate the clinical development and manufacturing of this vaccine candidate have been critical to enabling equitable access to the vaccine through COVAX," said Dr.
"Today's agreement with
Vaccine dose allocation will be determined by Gavi across the AMC-eligible and self-financing participants under a tiered pricing schedule.
"CEPI's early support served as a catapult for
About the COVAX Facility
The COVAX Facility is a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines that currently includes more than 190 participating economies, designed and administered by Gavi, the
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials, a trial in the
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
Novavax Forward Looking Statements
Statements herein relating to the future of
View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-and-gavi-execute-advance-purchase-agreement-for-covid-19-vaccine-for-covax-facility-301285703.html